Multibagger Selection: Gemini 1.5 Pro's picks
Gemini 1.5 Pro picked DLO, TBN, IRON, AGYS, VNDA with a twelve-month thesis, measured against SPY at each checkpoint.
| Experiment | Multibagger Selection |
|---|---|
| Model | Gemini 1.5 Pro |
| Prompt version | multibagger-selection-v1 |
| Asked | |
| Horizon | 12-month |
| Benchmark | SPY |
| Status | Being measured |
The picks
| Rank | Symbol | Return | Confidence | vs benchmark | Called right |
|---|---|---|---|---|---|
| 1 | DLO | — | 85% | — | — |
| 2 | TBN | — | 75% | — | — |
| 3 | IRON | — | 80% | — | — |
| 4 | AGYS | — | 70% | — | — |
| 5 | VNDA | — | 65% | — | — |
Checkpoints
| Checkpoint | Portfolio return | Return vs SPY | Best peak multiple | Picks reaching 2x |
|---|---|---|---|---|
| 1 week | -2.35% | -2.87% | 1.04x | 0 |
| 1 month | +1.40% | +2.36% | 1.26x | 0 |
The model's market view
The current environment for small and mid-cap equities is highly selective. While broader indices sit near all-time highs driven by mega-cap tech earnings, the Russell 2000 has lagged as investors remain cautious about sustained high interest rates and macroeconomic crosscurrents. However, this creates severe mispricings in the $200M–$5B range. Biotech companies with de-risked late-stage assets, SaaS firms demonstrating AI monetization, and resource companies near commercialization are prime candidates for extreme upside, as they rely on idiosyncratic catalysts rather than broad multiple expansion.
Why each pick
DLO
DLocal offers a rare combination of 50%+ top-line growth and GAAP profitability at a compressed valuation. The recent margin compression is a strategic byproduct of onboarding massive top-tier merchants, which secures long-term volume. A pristine balance sheet ($450M cash) provides a massive buffer. (Note: A live September 25, 2026 price quote could not be verified, so reference_price is omitted).
TBN
Tamboran Resources is a high-risk, high-reward E&P play sitting on a massive potential gas resource in Australia's Beetaloo Basin. Despite an auditor's going concern warning, the company recently raised $291M, securing the runway needed to execute its Phase I pilot. If flow rates prove commerciality, the asset's tier-1 scale will command a massive premium.
IRON
Disc Medicine is a clinical-stage biotech with a massive $791M cash pile (roughly 25% of its market cap). The market has aggressively re-rated the stock based on early clinical signals, but a definitive Phase 3 success in EPP could turn the company into a prime acquisition target for large pharma seeking rare disease assets.
AGYS
Agilysys is successfully penetrating the global hospitality software market. Net income is soaring, and the aggressive rollout of 30+ new AI-powered features provides a tangible catalyst to drive ARPU expansion and win market share from legacy providers like Oracle MICROS. (Note: A live September 25, 2026 price quote could not be verified, so reference_price is omitted).
VNDA
Vanda Pharmaceuticals is a deep-value turnaround play. The market has punished the stock due to HETLIOZ generic erosion, pushing the market cap down to near cash value. However, the recent approvals of BYSANTI and NEREUS, alongside multiple upcoming Phase 3 readouts, provide a clear path to replace lost revenue and hit management's $750M 2030 target.
Other models on the same run
| Model | Picks |
|---|---|
| Claude Opus 5.5 | INBX, CRML, LUNR, RDW, SRZN |
| Muse Spark 1.1 | ENVA, SMR, RARE, CAPR, INDP |
| Perplexity | LQDA, AAOI, CRDO, RDW, POET |
| Grok 4.5 | AESI, SOUN, PRME, MYRG, VSEC |
| GPT-5.6 Sol | CAPR, NTLA, BEAM, LUNR, RXRX |
| DeepSeek | QMLS, DUOT, TLSI, NUAI, OPTX |
ForecastNest provides AI-generated market analysis and quantitative research for informational and educational purposes only. Nothing here constitutes financial, investment, legal, or tax advice.